Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors

Opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial
: Gladman, D.D.; Rigby, W.F.C.; Azevedo, V.F.; Behrens, F.; Blanco, R.; Kaszuba, A.; Kudlacz, E.; Wang, C.; Menon, S.; Hendrikx, T.; Kanik, K.S.


Annals of the rheumatic diseases 76 (2017), Supplement 2, S.135-136
ISSN: 0003-4967
Annual European Congress of Rheumatology (EULAR) <2017, Madrid>
Fraunhofer IME ()